文献速递哮喘

噻托溴铵附加治疗在儿童哮喘患者中安全并减少季节性恶化

Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.
PubMed 文献 · Eur Respir J · 2019-06-13

该分析汇总了五项随机双盲安慰剂对照研究,评估噻托溴铵5或2.5微克附加治疗在1-17岁症状性哮喘患者中的安全性。共1691例患者接受治疗,其中1119例接受噻托溴铵。结果显示不良事件报告率低且组间均衡,噻托溴铵5微克组哮喘症状相关不良事件和恶化数量低于安慰剂组,尤其在季节性高峰期间。

要点

  • 噻托溴铵附加治疗在儿童哮喘患者中安全性良好,不良事件报告率与安慰剂相当。
  • 噻托溴铵5微克组哮喘症状相关不良事件和恶化数量低于安慰剂组。
  • 季节性高峰期间噻托溴铵减少哮喘相关不良事件的效应更明显。

核心结论

  • 每日一次噻托溴铵Respimat附加治疗在症状性儿童哮喘患者中安全性得到进一步支持。

研究设计与样本

  • 汇总五项随机双盲安慰剂对照研究,评估噻托溴铵5或2.5微克与安慰剂附加治疗在1-17岁症状性哮喘患者中的安全性。
  • 共1691例患者接受治疗,其中1119例接受噻托溴铵。

主要发现

  • 不良事件报告率:噻托溴铵5微克组51%,噻托溴铵2.5微克组51%,安慰剂组54%。
  • 药物相关不良事件、导致停药的不良事件及严重不良事件报告率低且组间均衡,不受年龄、疾病严重程度或性别影响。
  • 噻托溴铵5微克组哮喘症状相关不良事件和恶化数量低于安慰剂组,尤其在季节性高峰期间。

临床怎么用

  • 对于症状性儿童哮喘患者,可考虑每日一次噻托溴铵Respimat附加治疗以降低季节性哮喘恶化风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There remains an unmet need for effective, well-tolerated therapeutic options in paediatric patients with not fully controlled asthma, for whom safety is of paramount importance.Data were pooled from five randomised, double-blind, placebo-controlled studies evaluating tiotropium 5 or 2.5 µg versus placebo add-on therapy in patients with symptomatic asthma aged 1-17 years. Analysis included adverse events (AEs) and serious AEs (SAEs) reported throughout and for 30 days following treatment.Of 1691 patients treated, 1119 received tiotropium. Reporting of AEs was low and comparable across all groups: tiotropium 5 µg (51%), tiotropium 2.5 µg (51%) and placebo (54%). Reporting of drug-related AEs, those leading to discontinuation and SAEs was also low and balanced between treatment groups, irrespective of age, disease severity or sex. The number of AEs related to asthma symptoms and exacerbations was lower with tiotropium (5 µg) than with placebo, particularly during the seasonal peaks of these AEs.This comprehensive analysis of a large safety database allowed subgroup analyses that are often impractical with individual trials and provides further support for the safety of once-daily tiotropium Respimat add-on therapy in paediatric patients with symptomatic asthma.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Vogelberg C, Szefler SJ, Vrijlandt EJLE, et al. Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients. Eur Respir J. 2019. PMID: 31097514. doi:10.1183/13993003.01824-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。